Novavax (NVAX) Stock: $294 Target By H.C. Wainwright

By Amit Chowdhry ● May 16, 2021
  • The shares of Novavax, Inc. (NASDAQ: NVAX) have received a price target decrease from $317 to $294 by H.C. Wainwright. These are the details.

The shares of Novavax, Inc. (NASDAQ: NVAX) have received a price target decrease from $317 to $294 by H.C. Wainwright. And H.C. Wainwright analyst Vernon Bernardino is reiterating a “Buy” rating on the company shares.

Bernardino cited the company’s first quarter results in the research report. And Bernardino pointed out that with the focused implementation of robust COVID-19 vaccine clinical development programs and the initiation of booster arm studies with NVX-CoV2373, Novavax is “demonstrating long-term vision that ensures a future for widespread distribution and adoption of its COVID-19 vaccines.”

Going forward, Bernardino is expecting the company to remain a solid player in the COVID-19 vaccine landscape. And concerns over a delay in regulatory filings and manufacturing challenges are considered “only temporary setbacks,” according to Bernardino.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.